71 related articles for article (PubMed ID: 11553994)
1. Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model.
Blanchet PJ; Calon F; Morissette M; Goulet M; Grondin R; Lévesque D; Bédard PJ; Di Paolo T
Adv Neurol; 2001; 86():337-44. PubMed ID: 11553994
[No Abstract] [Full Text] [Related]
2. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
Blanchet PJ; Calon F; Martel JC; Bédard PJ; Di Paolo T; Walters RR; Piercey MF
J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
[TBL] [Abstract][Full Text] [Related]
3. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.
Goulet M; Morissette M; Calon F; Blanchet PJ; Falardeau P; Bédard PJ; Di Paolo T
Neuroscience; 1997 Jul; 79(2):497-507. PubMed ID: 9200732
[TBL] [Abstract][Full Text] [Related]
4. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
6. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
7. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Pope-Coleman A; Tinker JP; Schneider JS
Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
[TBL] [Abstract][Full Text] [Related]
8. Pulsatile administration of D1 but not D2 dopamine agonists induces behavioral tolerance in MPTP-treated monkeys.
Luquin MR; Guillén J; Legarda I; Cruz Rodriguez M; Del Rio L; Dominguez J; Martínez-Lage JM
Adv Neurol; 1996; 69():239-44. PubMed ID: 8615134
[No Abstract] [Full Text] [Related]
9. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors.
Wang JQ; McGinty JF
J Pharmacol Exp Ther; 1997 May; 281(2):972-82. PubMed ID: 9152408
[TBL] [Abstract][Full Text] [Related]
10. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
Betarbet R; Greenamyre JT
Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
[TBL] [Abstract][Full Text] [Related]
11. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
12. Striatal dopamine receptors in rats displaying long-term behavioural sensitization to morphine.
Nestby P; Schotte A; Janssen PF; Tjon GH; Vanderschuren LJ; De Vries TJ; Mulder AH; Leysen JE; Schoffelmeer AN
Synapse; 1997 Nov; 27(3):262-5. PubMed ID: 9329160
[No Abstract] [Full Text] [Related]
13. Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Prikhojan A; Brannan T; Yahr MD
J Neural Transm (Vienna); 2000; 107(10):1159-64. PubMed ID: 11129105
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Yoshimura N; Mizuta E; Yoshida O; Kuno S
J Pharmacol Exp Ther; 1998 Jul; 286(1):228-33. PubMed ID: 9655864
[TBL] [Abstract][Full Text] [Related]
15. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates.
Byrnes EM; Bruno JP
Dev Psychobiol; 1994 Sep; 27(6):409-24. PubMed ID: 8001729
[TBL] [Abstract][Full Text] [Related]
16. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
17. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats.
Le Foll B; Diaz J; Sokoloff P
Synapse; 2003 Mar; 47(3):176-83. PubMed ID: 12494400
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
19. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
20. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
